← back to the index
DV-008 breast implants 2019

The Allergan BIOCELL Implants — Textured Shells Tied to Cancer and 33 Deaths

cancer-bia-alcldeathoncologyplastic-surgery2010s
Patients implanted
Hundreds of thousands worldwide (millions of textured shells over the product life)
Failure or harm
573 BIA-ALCL cases globally at recall (481 Allergan); ≥33 deaths; ~6× the ALCL risk of other textured implants
In use
~13 yrs (Nov 2006 U.S. approval – Jul 2019 recall)
Status
Recalled (Class I)

Summary

When Allergan announced a voluntary worldwide recall of its BIOCELL textured breast implants and tissue expanders on July 24, 2019 — at the request of the U.S. Food and Drug Administration — the gap between the product's marketing and its documented harm was already a measurable oncologic toll: the FDA cited 573 unique cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) worldwide, of which 481 were attributable to Allergan devices, and 33 patient deaths, with 12 of the 13 deaths for which the implant maker was known confirmed to involve an Allergan implant. The agency's analysis put the BIA-ALCL risk of BIOCELL macrotextured shells at roughly six times that of textured implants from other manufacturers then on the U.S. market. The implant had been sold as an ordinary reconstructive and cosmetic option; what it delivered, in a small but non-trivial fraction of recipients, was a lymphoma growing in the scar capsule around the device.

The harm was not a manufacturing defect in the conventional sense — it was the shell's defining feature. BIOCELL was a macrotextured surface produced by a "salt-loss" process that pressed salt crystals into the silicone and dissolved them away, leaving a deeply pitted, high-surface-area shell originally marketed to anchor the implant and reduce capsular contracture. That same surface area is now the leading mechanistic suspect: it harbored more bacteria, sustained chronic biofilm and immune stimulation against the textured surface, and over years of low-grade inflammation appears to have driven T-cell transformation into ALCL in the periprosthetic capsule. The disease typically presented as a delayed seroma or mass years after implantation; caught early and treated by complete capsulectomy it was often curable, but advanced cases were lethal.

Regulators abroad moved first. France's medicines agency, the ANSM, declined to renew the CE mark for Allergan's macrotextured implants in December 2018 and in April 2019 became the first national regulator to ban macrotextured and polyurethane breast implants outright as a precaution. The FDA, which had publicly flagged a possible breast-implant/ALCL association as early as January 2011, did not force Allergan's hand until July 2019 — by which point hundreds of thousands of the shells were already in patients' bodies and would remain there, since neither the FDA nor Allergan recommended removing implants from asymptomatic women. As cumulative reporting matured, the case count climbed: by 2023 the FDA had documented on the order of 1,264 BIA-ALCL cases globally and 63 deaths, with roughly 85 percent of cases tied to Allergan textured devices. The BIOCELL recall became the modern textbook case of a device hazard that was rare, latent, and surface-intrinsic — and of a regulatory system that recognized the signal years before it acted on it.

Timeline

Nov 2006
FDA approves Allergan's Natrelle silicone implants
The Natrelle line (premarket application P020056), including BIOCELL macrotextured shells inherited from Inamed/McGhan, is approved for U.S. sale alongside the broader return of silicone-gel implants to the market.
Jan 2011
FDA's first ALCL safety communication
The FDA publicly reports a possible association between breast implants and anaplastic large cell lymphoma, citing roughly 34 identified cases worldwide, and calls the disease rare.
2016
WHO recognizes BIA-ALCL
The World Health Organization classifies breast implant-associated ALCL as a distinct provisional entity, formalizing it as a recognized lymphoma tied to implants.
2016–2018
Registry data implicate macrotexture
Australian/New Zealand and PROFILE-registry analyses repeatedly show the risk concentrated in high-surface-area textured shells, with BIOCELL among the highest-risk surfaces.
Dec 2018
CE mark lapses in Europe
Allergan's macrotextured BIOCELL and Microcell implants lose European marketing after the ANSM-linked notified body declines to renew the CE certificate; Allergan withdraws them from the EU.
Apr 2019
France bans macrotextured implants
The ANSM becomes the first national regulator to prohibit macrotextured and polyurethane breast implants as a precautionary measure against BIA-ALCL.
May 2019
FDA holds public advisory meeting
The FDA convenes a General and Plastic Surgery Devices Panel on breast-implant safety but stops short of an immediate U.S. ban, opting to gather more data.
Jul 24, 2019
Worldwide recall
At the FDA's request, Allergan announces a voluntary global recall of BIOCELL textured implants and tissue expanders; FDA cites 573 BIA-ALCL cases (481 Allergan) and 33 deaths.
Aug 2019
FDA orders patient notification
The FDA directs healthcare providers to stop implanting BIOCELL devices, return unused stock, and inform patients; it does not recommend explant of asymptomatic implants.
May 8, 2020
AbbVie completes acquisition of Allergan
AbbVie closes its ~$63 billion purchase of Allergan, inheriting the BIOCELL liability and the maturing BIA-ALCL litigation.
2021–2023
Case count and deaths rise
With longer follow-up, FDA-tracked BIA-ALCL totals climb to roughly 1,264 global cases and 63 deaths, ~85% tied to Allergan textured shells.

The Surface Sold as a Feature

BIOCELL was not an accident of manufacturing; it was a selling point. The shell's aggressive texture was produced by a salt-loss process — salt crystals pressed into the uncured silicone, then dissolved out — that left a deeply pitted surface with a vastly larger area than smooth or microtextured implants. Allergan and its predecessor Inamed marketed this macrotexture as a benefit: the rough surface promoted tissue adherence, was thought to reduce capsular contracture and implant rotation, and made BIOCELL a default choice for many reconstructive and cosmetic cases after silicone implants returned to the U.S. market under the November 2006 Natrelle approval. For more than a decade the product moved as routine inventory across dozens of countries. The very property promoted on the label — maximal surface contact between a foreign body and human tissue — was the property that would later be identified as the engine of harm. The wonder-surface narrative held precisely because the cancer it produced was rare enough, and slow enough, to stay below the threshold of clinical alarm for years.

A Lymphoma in the Capsule

The turn came not as a sudden failure but as a slowly accumulating epidemiological signal. BIA-ALCL is a T-cell lymphoma that arises in the fibrous capsule the body forms around an implant, typically presenting as a delayed fluid collection (seroma) or mass years after surgery. The mechanistic consensus that emerged points at the textured surface itself: its large area harbored more bacteria, sustained a chronic biofilm, and provoked persistent immune stimulation, and that long-running inflammation appears to drive malignant T-cell transformation. Crucially, the risk was not evenly distributed across implants — it tracked surface area. Registry studies in Australia, New Zealand, and the United States through the 2010s repeatedly found the hazard concentrated in high-grade textured shells, with BIOCELL among the worst. The FDA had named a possible implant-ALCL link as early as January 2011, when only about 34 cases were known; the WHO formalized BIA-ALCL as an entity in 2016. The disease was rare and often curable when caught early by complete capsule removal, but it was real, it was attributable to the device class, and the data increasingly singled out one surface.

The Regulators Move, Out of Order

The reckoning arrived through regulators, and the sequence indicted the lag as much as the device. Europe acted first by attrition: in December 2018 Allergan's macrotextured BIOCELL implants lost their CE mark when the certificate was not renewed, forcing withdrawal from the EU. France went further, and faster, than anyone: in April 2019 the ANSM banned macrotextured and polyurethane breast implants outright — the first national regulator in the world to do so — explicitly on precautionary grounds. The FDA, holding the largest implant market, convened a public advisory panel in May 2019 but declined an immediate ban, choosing to assemble more evidence. Only on July 24, 2019, did it request the voluntary worldwide recall Allergan then executed, citing 573 BIA-ALCL cases and 33 deaths. By then the shells were already inside hundreds of thousands of patients, and the agency's guidance was not to remove them from women without symptoms — meaning the recall halted future implantation without retrieving the in-body hazard. When AbbVie completed its acquisition of Allergan in May 2020, it inherited both the product's liabilities and the still-rising case count, which by 2023 had reached roughly 1,264 cases and 63 deaths worldwide.

Contributing Factors

01
A hazard intrinsic to the marketed feature
The harm did not come from a defective batch but from BIOCELL's defining macrotexture, the high-surface-area shell promoted as a clinical advantage. When the selling point and the failure mechanism are the same property, no quality-control fix exists short of abandoning the design — a category of risk that conventional manufacturing oversight is structurally blind to.
02
A rare, latent endpoint that masked the signal
BIA-ALCL presented years after implantation and at low absolute incidence, so individual surgeons and patients saw nothing alarming. Harms that are both delayed and statistically rare evade clinical intuition and surface only through large, long-horizon registries — exactly the surveillance that did not exist when the device launched.
03
Surveillance that lagged the deployment
The product was approved in 2006; the first FDA ALCL communication came in 2011; WHO recognition in 2016; recall in 2019. The detection-and-response apparatus trailed the device by more than a decade, allowing the exposed population to grow throughout the latency window before the hazard was acted upon.
04
Fragmented international regulation moving out of sequence
France banned macrotextured implants in April 2019; Europe had let the CE mark lapse in December 2018; the FDA waited until July 2019. Patients' protection depended on which jurisdiction they lived in, and the largest market acted last — a coordination failure that left identical devices simultaneously banned in one country and routinely implanted in another.
05
Withdrawal without retrieval
The recall stopped new implantation but explicitly did not call for explanting asymptomatic patients, leaving hundreds of thousands of the implicated shells in bodies. Treating cessation of sales as the endpoint — rather than the residual in-body risk — meant the recall capped future exposure without resolving the existing one.

Aftermath

The BIOCELL recall reshaped the breast-implant field rather than ending it. Macrotextured implants were effectively driven from the market in much of the world; surgeons shifted decisively toward smooth-surface devices, and BIA-ALCL became a standard element of informed-consent discussions for any textured implant. The financial and legal exposure passed to AbbVie when it absorbed Allergan in May 2020, and BIA-ALCL claims proceeded through the courts as the device action itself stood closed. For regulators, the episode became a reference point in the broader post-market-surveillance reckoning that the Implant Files investigation had ignited in 2018: a documented instance in which the safety signal was visible for years — flagged by the FDA in 2011, formalized by the WHO in 2016, acted on by France in 2019 — before the largest market moved. The case count's continued climb after recall, to over 1,200 cases and 63 deaths by 2023, underscored the central lesson: with a latent oncologic device, the body count keeps accruing long after the product is pulled. BIOCELL is now the byword for a hazard that lived in the surface, hid in the latency, and exposed how slowly a fragmented regulatory system converts a recognized signal into action.

Lessons

  1. Treat a device's marketed differentiator as a primary suspect when harm emerges; when the selling feature and the failure mechanism are the same property, no recall of "defective units" will help — the design itself is the defect.
  2. Build long-horizon registries before, not after, a device with a plausible latent endpoint reaches market; rare, delayed harms are invisible to individual clinicians and surface only in pooled, multi-year data.
  3. Measure regulatory performance by the lag between signal recognition and action, not by the action alone — a hazard named in 2011 and recalled in 2019 is a surveillance failure regardless of how the recall reads.
  4. Harmonize cross-border device action, or accept that patients are protected by accident of geography; identical implants banned in Paris and routinely placed elsewhere is a coordination failure, not a scientific disagreement.
  5. Distinguish withdrawal from retrieval: halting sales does nothing for the implanted population, so define the obligation around the in-body hazard and the surveillance owed to exposed patients, not merely the end of distribution.

References